Trials / No Longer Available
No Longer AvailableNCT02186249
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | |
| DRUG | Ipilimumab |
Timeline
- First posted
- 2014-07-10
- Last updated
- 2017-02-08
Locations
66 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02186249. Inclusion in this directory is not an endorsement.